Therapeutic Potential and Challenges of Cannabis sativa in Neurological Disorders: Pathways to Integration into Health Systems
DOI:
https://doi.org/10.70151/np6wdt13Keywords:
Phytocannabinoids, coconvulsive states in children, CBD, nervous system disorders, SUS, BrazilAbstract
Cannabis sativa L., commonly known as marijuana, has historically been used for medicinal and recreational purposes. Recent studies highlight its therapeutic potential for various neurological conditions, such as epilepsy, multiple sclerosis, and Parkinson's disease. The main bioactive components, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have distinct therapeutic properties: THC is known for its psychoactive and analgesic effects, while CBD, which is non-psychoactive, displays anti-inflammatory, anxiolytic, and anticonvulsant effects. In Brazil, research on the medicinal effects of Cannabis sativa has intensified with significant initiatives from renowned researchers. This article reviews the existing literature on the pharmacological properties of phytocannabinoids, advances in pre-clinical and clinical research, and prospects for the regulation and implementation of these treatments in the Brazilian Unified Health System (SUS). The inclusion of Cannabis in the SUS presents regulatory and production challenges but has significant potential to benefit many patients, effectively and safely meeting their health needs.
Downloads
References
Aran A, Harel M, Cassuto H, Polyansky L, Schnapp A, Wattad N, Shmueli D, Golan D, Castellanos FX (2021) Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism 3:12(1):6. https://doi. org/10.1186/s13229-021-00420-2.
Argueta DA, Ventura CM, Kiven S, Sagi V, Gupta K (2020) A balanced approach for cannabidiol use in chronic pain. Front Pharmacol 30(11):561. https:doi.org/10.3389/ fphar.2020.00561.
Arzimanoglou A, Brandl U, Cross JH, Gil-Nagel A, Lagae L, Landmark CJ, Specchio N, Nabbout R, Thiele EA, Gubbay O, The cannabinoids international experts panel; collaborators (2020) Epilepsy and cannabidiol: A guide to treatment. Epileptic Disord 22:1-14. https:// doi.org/10.1684/epd.2020.1141
Bennici A, Mannucci C, Calapai F, Cardia L, Ammendolia I, Gangemi S, Calapai G, Soler DC (2021) Safety of medical 11:561. https://doi.org/10.3389/fphar.2020.00561
Bergamaschi MM, Queiroz RHC, Chagas MHN, Oliveira DCG, Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Santos RM, Hallak JEC, Zuardi AW, Crippa JAS (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacol 36:1219- 1226. https://doi.org/10.1038/npp.2011.6
Bhunia S, Kolishetti N, Arias AY, Vashist A, Nair M (2022) Cannabidiol for neurodegenerative disorders: A comprehensive review. Front Pharmacol 13:989717. https://doi.org/10.3389/fphar.2022.989717
Bilbao A, Spanagel R (2022) Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. https://doi.org/10.1186/s12916-022-02459-1
Bitencourt D (2024) Embrapa tem condições para iniciar pesquisas sobre produção de cânhamo no Brasil. Embrapa. Disponível em: https://www.embrapa.br. Acesso em: 14 nov. 2024.
Bittencourt DMC (2024) EMBRAPA Genetic Resources & Biotechnology. Disponível em: https://www.embrapa.br/ en/pesquisa. Accessed em: October 20, 2024
Boyaji S, Merkow J, Elman RN, Kaye AD, Yong RJ, Urman RD (2020) The role of cannabidiol (CBD) in chronic pain management: An assessment of current evidence. Curr Pain Headache Rep 24:4. https://doi.org/10.1007/ s11916-020-0835-4
Brazil (2015) Bill No. 399, of 2015. Provides for the regulation of the cultivation, processing, research, production, and commercialization of Cannabis-based products for medicinal, veterinary, and industrial purposes. Chamber of Deputies, Brasília, DF. Available at: https://www.camara.leg.br/proposicoesWeb/ fichadetramitacao?idProposicao=2083127. Accessed on: October 20, 2024.
Brazil (2024) National Health Surveillance Agency. Available at: https://consultas.anvisa.gov.br/#/cannabis/. Accessed on: May 9, 2024.
Brazil (2024) National Health Surveillance Agency. Available at: https://www.gov.br/anvisa/pt-br/ assuntos/regulamentacao/air/analises-de-impacto-regulatorio/2024/arquivos-relatorios-de-air-2024/ relatorio-de-air-produtos-cannabis-medicinal-08082024. pdf. Accessed on: October 20, 2024.
Calapai F, Cardia L, Esposito E, Ammendolia I, Mondello C, Giudice RL, Gangemi S, Calapai G, Mannucci C (2022) Pharmacological aspects and biological effects of cannabigerol and its synthetic derivatives. Evid Based Complement Alternat Med https://doi. org/10.1155/2022/3336516.
Campos AC, Fogaça MV, Scarante FF, Joca SRL, Sales AJ, Gomes FV, Sonego AB, Rodrigues NS, Galve-Roperh I, Guimarães FS (2017) Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders. Front Pharmacol 23;8:269. https://10.3389/fphar.2017.00269.
Campos AC, Fogaça MV, Sonego AB, Guimarães FS (2016) Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res 112:119-127. https://doi. org/10.1016/j.phrs.2016.01.033
Campos AC, Guimarães FS (2020) Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders. Front Pharmacol 11:618065. https://doi.org/10.3389/fphar.2020.618065
Campos RMP, Aguiar AFL, Colli YP, Trindade PMP, Ferreira BK, Reis RAM, Sampaio LS (2021) Cannabinoid therapeutics in chronic neuropathic pain: From animal research to human treatment. Front Physiol 12:785176. https://doi.org/10.3389/fphys.2021.785176
Cannabis in neuropathic chronic pain management. Molecules 26:6257. https://doi.org/10.3390/ molecules26206257
Carlini EA (2010) Pesquisas com a maconha no Brasil. Bras. Psiquiatr 32:3-4. https://doi.org/10.1590/S1516- 44462010000500002
Carter GT, Abood ME, Aggarwal SK, Weiss MD (2010) Cannabis and amyotrophic lateral sclerosis: Hypothetical and practical applications, and a call for clinical trials. Am J Hosp Palliat Care 27:347-356. https://doi. org/10.1177/1049909110369531
Cassano T, Villani R, Pace L, Carbone A, Bukke VN, Orkisz S, Avolio C, Serviddio G (2020) From Cannabis sativa to cannabidiol: Promising therapeutic candidate for the treatment of neurodegenerative diseases. Front Pharmacol 11:124. https://doi.org/10.3389/ fphar.2020.00124
Castro CGSO, Esher A, Du Bocage C, Oliveira CV (2024) Entrevista: pesquisadoras falam sobre uso medicinal da cannabis, regulação e estudos. Fiocruz Notícias. Disponível em: https://portal.fiocruz.br/noticia/2024/10/ entrevista-pesquisadoras-falam-sobre-uso-medicinal-da-cannabis-regulacao-e-estudos. Acesso em: 13 nov. 2024.
Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, Freeman TP, McGuire P (2020) Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 45:1799-1806. https://doi.org/10.1038/s41386-020- 0667-2
Crippa JA, Guimarães FS, Campos AC, Zuardi AW (2018) Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Front Immunol 9:2009. https://doi.org/10.3389/fimmu.2018.02009
Crippa JAS, Guimarães FS, Zuardi AW, Hallak JEC. Dr. Raphael Mechoulam, Cannabis and cannabinoids research pioneer (November 5, 1930–March 9, 2023) and his legacy for Brazilian pharmacology. Braz J Psychiatry. 2023 Jun 8;45(3):201–2. https://doi. org/10.47626/1516-4446-2023-0047
Cristino L, Bisogno T, Di Marzo V (2020) Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol 16:9–29. https://doi. org/10.1038/s41582-019-0284-z
De Souza MR, Henriques AT, Limberger RP (2022) Medical Cannabis regulation: An overview of models around the world with emphasis on the Brazilian scenario. J Cannabis Res 4:33. https://doi.org/10.1186/s42238- 022-00142-z
Devinsky O, Jones NA, Cunningham MO, Jayasekera BAP, Devore S, Whalley BJ (2024) Cannabinoid treatments in epilepsy and seizure disorders. Physiol Rev 1;104(2):591-649. https://doi.org/10.1152/ physrev.00049.2021.
Do Amaral MD and Posso IP (2023) Current legislation on medical cannabis. History, movements, trends and counter-tendencies, in the Brazilian territory. BrJ P 6: 75-79. https://doi.org/10.5935/2595-0118.20230026-en
Doyle A, Harvey J (2019) Cannabis and epilepsy. J Dual Diagn 16:75-82. https://doi.org/10.1080/15504263.201 9.1645372
Elsaid S, Kloiber S, Le Foll B (2019) Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Prog Mol Biol Transl Sci 167:25-75. https://doi.org/10.1016/ bs.pmbts.2019.06.005
Faiz MB, Naeem F, Irfan M, Aslam MA, Estevinho LM, Ateşşahin DA, Alshahrani AM, Calina D, Khan K, Sharifi-Rad J. Exploring the therapeutic potential of cannabinoids in cancer by modulating signaling pathways and addressing clinical challenges. Discov Oncol 15(1):490. https://doi.org/10.1007/s12672-024- 01356-8
Ferreira-Junior NC, Campos AC, Guimarães FS, Del-Bel E, Zimmermann PMR, Junior LB, Hallak JE, Crippa JA, Zuardi AW (2020) Biological bases for a possible effect of cannabidiol in Parkinson’s disease. Braz J Psychiatry 42:218-224. https://doi.org/10.1590/1516- 4446-2019-0460
Fiocruz (2023) Institutional Program on Drug Policy, Human Rights and Mental Health. Available at: https:// www.who.int/publications/m/item/ecdd-41-cannabis-recommendations. Accessed on: April 18, 2023.
Fragoso YD, Carra A, Macias MA (2020) Cannabis and multiple sclerosis. Expert Rev Neurother 20:849-854. https://doi.org/10.1080/14737175.2020.1776610
Fundação Oswaldo Cruz (Fiocruz). Nota Técnica: Estado atual das evidências sobre usos terapêuticos da cannabis e derivados e a demanda por avanços regulatórios no Brasil. 2023. Disponível em: https:// portal.fiocruz.br/documento/nota-tecnica-do-programa-institucional-de-politicas-de-drogas-direitos-humanos-e-saude. Acesso em: 13 nov. 2024.
Fundação Oswaldo Cruz (Fiocruz). Ordinance No. 192, of March 8, 2023. Institutional Program on Drug Policies, Human Rights, and Mental Health. SEI/FIOCRUZ - 2553132. Available at: . Accessed on: November 14, 2024.
Golub V, Reddy DS (2021) Cannabidiol therapy for refractory epilepsy and seizure disorders. Adv Exp Med Biol 1264:93-110. https://doi.org/10.1007/978-3- 030-57369-0_7
Hacohen M, Stolar OE, Berkovitch M, Elkana O, Kohn E, Hazan A, Heyma E, Sobol Y, Waissengreen D, Gal E, Disteins I (2022) Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study. Transl Psychiatry 12:375. https://doi. org/10.1038/s41398-022-02104-8
Haddad F, Dokmak G, Karaman R (2022) The efficacy of Cannabis on multiple sclerosis-related symptoms. Life 12:682. https://doi.org/10.3390/life12050682
Hansen JS, Gustavsen S, Roshanisefat H, Kant M, Biering-Sørensen F, Andersen C, Olsson A, Chow HH, Asgari N, Hansen JR, Nielsen HH, Hansen RM, Petersen T, Oturai AB, Sellebjerg F, Sædder EA, Kasch H, Rasmussen PV, Finnerup NB, Svendsen KB (2023)
Cannabis-based medicine for neuropathic pain and spasticity-a multicenter, randomized, double-blinded, placebo-controlled trial. Pharmaceuticals 28;16(8):1079. https://doi.org/10.3390/ph16081079
Hidding U, Mainka T, Buhmann C (2024) Therapeutic use of medical Cannabis in neurological diseases: A clinical update. J Neural Transm 131:117-126. https:// doi.org/10.1007/s00702-023-02719-1
Hinz B, Ramer R (2022) Cannabinoids as anticancer drugs: current status of preclinical research. Br J Cancer 127:1–13. https://doi.org/10.1038/s41416-022-01727-4
Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP (2019) Cannabidiol adverse effects and toxicity. Curr Neuropharmacol. 2019;17(10):974-989. https://doi.org/10.2174/1570159X17666190603171901
Ibsen EWD, Thomsen PH (2024) Cannabinoids as alleviating treatment for core symptoms of autism spectrum disorder in children and adolescents: a systematic review. Nord J Psychiatry 78(7):553-560. https://doi.org/10.1080/08039488.2024.2381541
Iffland K, Grotenhermen F (2017) An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 1;2(1):139-154. https://doi.org/10.1089/can.2016.0034
Ingram G, Pearson OR (2019) Cannabis and multiple sclerosis. Pract Neurol 19:310-315. https://doi. org/10.1136/practneurol-2018-002137
Joca S, Guimarães FS (2024) The therapeutic potential of cannabidiol in neuropsychiatric and neurodegenerative disorders. Acta Neuropsychiatr 36(5):253-254. https:// doi.org/10.1017/neu.2024.48
Jotz GP, Ortiz RS, Limberger RP, de Oliveira Camargo FA (2024) Cannabidiol (CBD): Potential use in otorhinolaryngology. Int Arch Otorhinolaryngol 28(1):e1- e2. https://doi.org/10.1055/s-0043-1777857
Kopustinskiene DM, Masteikova R, Lazauskas R, Bernatoniene J (2022) Cannabis sativa L. bioactive compounds and their protective role in oxidative stress and inflammation. Antioxidants 11:660. https://doi. org/10.3390/antiox11040660
Köstenberger M, Nahler G, Jones TM, Neuwersch S, Likar R (2022) The role of Cannabis, cannabidiol and other cannabinoids in chronic pain. The perspective of physicians. J Neuroimmune Pharmacol 17:318–333. https://doi.org/10.1007/s11481-021-10010-x
Kumar P, Mahato DK, Kamle M, Borah R, Sharma B, Pandhi S, Tripathi V, Yadav HS, Devi S, Patil U, Xiao J, Mishra AK (2021) Pharmacological properties, therapeutic potential, and legal status of Cannabis sativa L.: An overview. Phytother Res 35:6010-6029. https:// doi.org/10.1002/ptr.7213
Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, Silvestrini M (2018) Efficacy and safety of cannabidiol in epilepsy: A systematic review and meta-analysis. Drugs 78(17):1791-1804. https://doi. org/10.1007/s40265-018-0992-5
Legare CA, Raup-Konsavage WM, Vrana KE (2022) Therapeutic potential of Cannabis, cannabidiol, and cannabinoid-based pharmaceuticals. Pharmacol 107:131-149. https://doi.org/10.1159/000521683
Lopes R (2023) Estados aprovam distribuição de Cannabis medicinal pelo SUS em meio a indefinição federal. Folha de S.Paulo. Disponível em: https://www1.folha. uol.com.br/equilibrioesaude/2023/07/estados-aprovam-distribuicao-de-cannabis-medicinal-pelo-sus-em-meio-a-indefinicao-federal.shtml. Acesso em: 13 nov. 2024.
Madeo G, Kapoor A, Giorgetti R, Busardò FP, Carlier J (2023) Update on cannabidiol clinical toxicity and adverse effects: A systematic review. Curr Neuropharmacol 21(11):2323-2342. https://doi.org/10. 2174/1570159X21666230322143401
Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Cas RD, Ippolito FM, Calapai G (2017) Neurological aspects of medical use of cannabidiol. CNS Neurol Disord Drug Targets 16(5):541-553. https://doi.org/10. 2174/1871527316666170413114210
Martins DA; Posso IP (2023) Current legislation on medical Cannabis. History, movements, trends and counter-tendencies, in the Brazilian territory. BrJP 6:75-79. https://doi.org/10.5935/2595-0118.20230026-en.
Meyer T, Funke A, Münch C, Kettermann D, Maier A, Walter B, Thomas A, Spittel S (2019) Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol: cannabidiol (THC:CBD). BMC Neurol 19:222. https:// doi.org/10.1186/s12883-019-1443-y
Mohammed SYM, Leis K, Mercado RE, Castillo MMS, Miranda KJ, Carandang RR (2024) Effectiveness of cannabidiol to manage chronic pain: A systematic review. Pain Manag Nurs 25(2):e76-e86. https://doi. org/10.1016/j.pmn.2023.10.002
Morano A, Fanella M, Albini M, Cifelli P, Palma E, Giallonardo AT, Di Bonaventura C (2020) Cannabinoids in the treatment of epilepsy: Current status and future prospects. Neuropsychiatr Dis Treat 16:381-396. https:// doi.org/10.2147/NDT.S203782
Moreira GA, Neto RM, Ribeiro RG, Crippa ACS (2022) Cannabidiol for the treatment of refractory epilepsy in children: A critical review of the literature. Rev Paul Pediatr 41:e2021197. https://doi.org/10.1590/1984- 0462/2023/41/2021197
Mostafavi M, Gaitanis J (2020) Autism spectrum disorder and medical Cannabis: review and clinical experience. Semin Pediatr Neurol. 35:100833. https:// doi.org/10.1016/j.spen.2020.100833
Oliveira MB, Vieira MS, Akerman M (2020) O autocultivo de Cannabis e a tecnologia social. Saúde Soc 29(3). https://doi.org/10.1590/S0104-12902020190856
Omotayo OP, Lemmer Y, Mason S (2024) A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders. J Cannabis Res 6(1):14. https://doi.org/10.1186/s42238-024-00222-2
Oshiro CA, Castro LHM (2022) Cannabidiol and epilepsy in Brazil: A current review. Arq Neuropsiquiatr 80:182-192. https://doi.org/10.1590/0004-282X-ANP-2022-S137
Ozarowski M, Karpiński TM, Zielińska A, Souto EB, Wielgus K (2021) Cannabidiol in neurological and neoplastic diseases: Latest developments on the molecular mechanism of action. Int J Mol Sci 22:4294. https://doi.org/10.3390/ijms22094294
Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C (2022) Cannabinoids: Therapeutic use in clinical practice. Int J Mol Sci 23:3344. https://doi. org/10.3390/ijms23063344
Pantoja-Ruiz C, Restrepo-Jimenez P, Castañeda-Cardona
C, Ferreirós A, Rosselli D (2022) Cannabis and pain: A scoping review. Braz J Anesthesiol 72:142-151. https:// doi.org/10.1016/j.bjane.2021.06.018
Parker LA, Rock EM, Limebeer CL (2011) Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol. 163(7):1411-22. https://doi.org/10.1111/ j.1476-5381.2010.01176.x
Patricio F, Morales-Andrade AA, Patricio-Martínez A, Limón ID (2020) Cannabidiol as a therapeutic target: Evidence of its neuroprotective and neuromodulatory function in Parkinson’s disease. Front Pharmacol 11:595635. https://doi.org/10.3389/fphar.2020.595635
Patti F, Chisari C, Solaro C, Benedetti MD, Berra E, Bianco A, Bossio RB, Buttari F, Castelli L, Cavalla P, Cerqua R, Costantino G, Gasperini C, Guareschi A, Ippolito D, Lanzillo R, Maniscalco GT, Matta M, Paolicelli D, Petrucci L, Pontecorvo S, Righini I, Russo M, Sacca F, Salamone G, Signoriello E, Spinicci G, Spitaleri D, Tavazzi E, Trotta M, Zaffaroni M, Zappia (2020) Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. Neurol Sci 41:2905– 2913. https://doi.org/10.1007/s10072-020-04413-6
Pedrazzi JFC, Ferreira FR, Silva-Amaral D, Lima DA, Hallak JEC, Zuardi AW, Del-Bel EA, Guimarães FS, Costa KCM, Campos AC, Crippa ACS, Crippa JAS (2022) Cannabidiol for the treatment of autism spectrum disorder: hope or hype?. Psychopharmacol 239:2713– 2734. https://doi.org/10.1007/s00213-022-06196-4
Pertwee RG (2020) The 90th Birthday of Professor Raphael Mechoulam, a top cannabinoid scientist and pioneer. Int J Mol Sci 21(20):7653. https://10.3390/ ijms21207653
Peters EN, MacNair L, Mosesova I, Christians U, Sempio C, Klawitter J, Land MH, Ware MA, Turcotte C, Bonn-Miller MO (2022) Pharmacokinetics of cannabichromene in a medical Cannabis product also containing cannabidiol and Δ9-tetrahydrocannabinol: A pilot study. Eur J Clin Pharmacol 78:259–265. https://doi.org/10.1007/s00228- 021-03232-8
Petzke F, Tölle T, Fitzcharles MA, Häuser W (2022) Cannabis-based medicines and medical Cannabis for chronic neuropathic pain. CNS Drugs 36:31-44. https:// doi.org/10.1007/s40263-021-00879-w
Quintero JM, Pulido G, Giraldo LF, Leon MX, Diaz LE, Bustos RH (2022) A systematic review on cannabinoids for neuropathic pain administered by routes other than oral or inhalation. Plants 11:1357. https://doi. org/10.3390/plants11101357
Radwan MM, Chandra S, Gul S, ElSohly MA (2021) Cannabinoids, phenolics, terpenes and alkaloids of Cannabis. Molecules 26:2774. https://doi.org/10.3390/ molecules26092774
Ribeiro S (2022) Saúde: pesquisa e uso da cannabis avançaram no Brasil nos últimos anos. Veja. Disponível em: https://veja.abril.com.br/saude/saude-pesquisa-e-uso-da-cannabis-avancaram-no-brasil-nos-ultimos-anos/. Acesso em: 13 nov. 2024.
Rieder CR (2020) Cannabidiol in Parkinson’s disease. Braz J Psychiatry 42:126-127. https://doi.org/10.1590/1516- 4446-2019-0810
Rock EM, Limebeer CL, Pertwee RG, Mechoulam R, Parker LA (2021) Therapeutic potential of cannabidiol, cannabidiolic acid, and cannabidiolic acid methyl ester as treatments for nausea and vomiting. Cannabis Cannabinoid Res 6(4):266-274. https://doi.org/10.1089/ can.2021.0041
Rock EM, Sticht MA, Limebeer CL, Parker LA. Cannabinoid regulation of acute and anticipatory nausea. Cannabis Cannabinoid Res. 2016 1(1):113-121. https://doi. org/10.1089/can.2016.0006
Ross IA (2023) Cannabis and multiple sclerosis. In: Ross IA. Plant-Based Therapeutics, Volume 1. Springer, Cham, 2023. 363–426.
Ryan M (2020) Cannabidiol in epilepsy: The indications and beyond. Ment Health Clin 10:317-325. https://doi. org/10.9740/mhc.2020.11.317
Schabas AJ, Vukojevic V, Taylor C, Thu Z, Badyal A, Chan JK, Devonshire V, Traboulsee A, Sayao AL, Carruthers R (2019) Cannabis-based product use in a multiple sclerosis cohort. Mult Scler J Exp Transl Clin 5:2055217319869360. https://doi. org/10.1177/2055217319869360
Schier AR, Ribeiro NPO, Silva ACO, Hallak JEC, Crippa JAS, Nardi AE, Zuardi AW (2012) Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Braz J Psychiatry 34:S104-110. https://doi.org/10.1590/s1516- 44462012000500008
Seltzer ES, Watters AK, MacKenzie D Jr, Granat LM, Zhang D (2020) Cannabidiol (CBD) as a Promising Anti-Cancer Drug. Cancers 12(11):3203. https://doi. org/10.3390/cancers12113203
Shalata W, Abu Saleh O, Tourkey L, Shalata S, Neime AE, Abu Juma’a A, Soklakova A, Tourkey L, Jama AA, Yakobson A (2024) The efficacy of cannabis in oncology patient care and its anti-tumor effects. Cancers 16(16):2909. https://doi.org/10.3390/cancers16162909
Shehata I, Hashim A, Elsaeidy AS, Nair A, Urits I, Viswanath O, Kaye AD, Habib M (2022) Cannabinoids and their role in chronic pain treatment: Current concepts and a comprehensive review. Health Psychol Res 10:35848. https://doi.org/10.52965/001c.35848
Sholler DJ, Schoene L, Spindle TR (2020) Therapeutic efficacy of cannabidiol (CBD): A review of the evidence from clinical trials and human laboratory studies. Curr Addict Rep 7:405-412. https://doi.org/10.1007/s40429- 020-00326-8
Silva EAD Junior, Medeiros WMB, Santos JPMD, Sousa JMM, Costa FBD, Pontes KM, Borges TC, Espínola C Neto Segundo, Andrade E Silva AH, Nunes ELG, Alves NT, Rosa MDD, Albuquerque KLGD (2024) Evaluation of the efficacy and safety of cannabidiol-rich Cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. Trends Psychiatry Psychother 46:e20210396. https://doi.org/10.47626/2237-6089- 2021-0396
Silva EAD Junior, Medeiros WMB, Torro N, Sousa JMM, Almeida IBCM, Costa FBD, Pontes KM, Nunes ELG, Rosa MDD, Albuquerque KLGD (2022) Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. Trends Psychiatry Psychother 44:e20200149. https://doi.org/10.47626/2237-6089- 2020-0149
Silva GD, Guerra FBD, Lelis MO, Pinto LF (2020) Cannabidiol in the treatment of epilepsy: A focused review of evidence and gaps. Front Neurol 11:531939. https://doi.org/10.3389/fneur.2020.531939
Singh K, Bhushan B, Chanchal DK, Sharma SK, Rani K, Yadav MK, Porwal P, Kumar S, Sharma A, Virmani T, Kumar G, Noman AA (2023) Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review. Behav Neurol. https://doi.org/10.1155/2023/8825358
Sirbu CA, Georgescu R, Pleşa FC, Paunescu A, Ţânţu MM, Nicolae AC, Caloianu I, Mitrica M (2023) Cannabis and cannabinoids in multiple sclerosis: From experimental models to clinical practice—a review. Am J Ther 30:e220-e231. https://doi.org/10.1097/ MJT.0000000000001568
Śmiarowska M, Białecka M, Machoy-Mokrzyńska A (2022) Cannabis and cannabinoids: Pharmacology and therapeutic potential. Neurol Neurochir Pol 56:4–13. https://doi.org/10.5603/PJNNS.a2022.0015
Solmi M, Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, Firth J, Miola A, Croatto G, Baggio F, Michelon S, Ballan L, Gerdle B, Monaco F, Simonato P, Scocco P, Ricca V, Castellini V, Fornaro M, Murru A, Vieta E, Fusar-Poli P, Barbui C, Ioannidis JPA, Carvalho AF, Radua J, Correll CU, Cortese S, Murray RM, Castle D, Shin JII, Dragioti E (2023) Balancing risks and benefits of Cannabis use: Umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ 382:e072348. https://doi.org/10.1136/bmj-2022- 072348
Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, Herkes GK, Farrell M, Degenhardt L (2018) Evidence for Cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. Journal of Neurology, Neurosurgery & Psychiatry 89:741-753. https://doi.org/10.1136/jnnp- 2017-317168
Treves N, Mor N, Allegaert K, Bassalov H, Berkovitch M, Stolar OE, Matok I (2021) Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis. Sci Rep 11:23462. https://doi.org/10.1038/ s41598-021-02770-6
Viana MB, Aquino PEA, Estadella D, Ribeiro DA, Viana GSB (2022) Cannabis sativa and cannabidiol: A therapeutic strategy for the treatment of neurodegenerative diseases? Med Cannabis Cannabinoids 5:207-219. https://doi.org/10.1159/000527335
Villanueva MRB, Joshaghani N, Villa N, Badla O, Goit R, Saddik SE, Dawood SN, Rabih AM, Niaj A, Raman A, Uprety M, Calero M, Khan S (2022) Efficacy, safety, and regulation of cannabidiol on chronic pain: A systematic review. Cureus 14:e26913. https://doi.org/10.7759/ cureus.26913
Von Wrede R, Helmstaedter C, Surges R (2021) Cannabidiol in the Treatment of Epilepsy. Clin Drug Investig 41(3):211-220. https://doi.org/10.1007/s40261- 021-01003-y
Wang F, Dezfouli AB, Khosravi M, Sievert W, Stangl S, Schwab M, Wu Zhiyuan, Steiger K, Ma H, Multhoff G (2023) Cannabidiol-induced crosstalk of apoptosis and macroautophagy in colorectal cancer cells involves p53 and Hsp70. Cell Death Discov 9:286. https://doi. org/10.1038/s41420-023-01578-9
Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J (2015) Cannabinoids for medical use: A systematic review and meta-analysis. JAMA 30:313(24):2456-73. https://doi. org/10.1001/jama.2015.6358
Wu J (2019) Cannabis, cannabinoid receptors, and endocannabinoid system: Yesterday, today, and tomorrow. Acta Pharmacol Sin 40:297-299. https://doi. org/10.1038/s41401-019-0210-3
Younes M, Hage ME, Shebaby W, Toufaily SA, Ismail J, Naim HY, Mroueh M, Rizk S (2024) The molecular anti-metastatic potential of CBD and THC from Lebanese Cannabis via apoptosis induction and alterations in autophagy. Sci Rep 14:25642. https://doi.org/10.1038/ s41598-024-76340-x
Zettl UK, Rommer P, Hipp P, Patejdl R (2016) Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord 9(1):9- 30. https://doi.org/10.1177/1756285615612659
Zuardi AW, Crippa JA (2023) Fifty years of research on cannabidiol (CBD) as an anticonvulsant: The legacy of Brazilian groups. Braz J Psychiatry 45(6):463-464. https://doi.org/10.47626/1516-4446-2023-3377
Zuardi AW, Crippa JAS, Hallak JEC, Moreira FA, Guimarães FS (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39:421-429. https://doi.org/10.1590/s0100- 879x2006000400001
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Revista Brasileira de Plantas Medicinais
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
